65,437 trials
Influenza
Primary: Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain. — 589.8; 933.1 Titers
Lip Augmentation
Primary: Percentage of Participants With Response — 92.6; 28.9 Percentage of Participants
Smoking · Bipolar Disorder · Depression
Primary: Carbon Monoxide Breath Level at 12 Weeks — 6 ppm
Renal Artery Obstruction · Hypertension, Renal
Primary: Binary Restenosis Rate — 10.5 Percentage of lesions — p=< 0.0001
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change in Intraocular Pressure at Day 1 — -4.16; -4.57; -0.60 mmHg
Diabetes Mellitus, Type II · Fatty Liver
Primary: Insulin Resistance and Glucose Homeostasis — .69; .24; -0.51; .73 mg/kg/min — p=0.040
Renal Calculus · Kidney Stones
Primary: Pain 'Right Now' — 1.0; 0.9 units on a scale
Leukaemia, Lymphocytic, Chronic
Primary: Number of Participants With a Dose-limiting Toxicity (DLT) — 0 participants
Coronary Artery Disease
Primary: Target Lesion Failure (TLF) — 2.9; 3.4 percentage of participants — p=0.001
Nephrectomy · Laparoscopic Donor Nephrectomy
Primary: Pain 'Right Now' — 2.4; 3.1 units on a scale
Parkinson Disease
Primary: Change in Stride Length From Baseline — 1.19 CM
Depression - Major Depressive Disorder
Primary: Area Under the Plasma Concentration-time Profile From Time 0 to 48 Hours (AUC48) — 2948; 2966; 2632; 2777 ng*hr/mL
Urogential Chlamydia Trachomatis Infection
Primary: Microbiological Cure Rate — 94.9; 94.6 percentage of participants cured
Advanced Solid Tumors
Primary: Excretion Balance of Radio-labeled 14C-eribulin: Total Recovery of Radioactive Dose in Urine and Feces. — 90.4 percent recovery
Pulmonary Hypertension
Primary: Number of Participants With Pulmonary Arterial Hypertension (PAH) Who Completed the Phase II NCT00046319 Study and Who Experienced Severe Adverse Events (AEs) During…